Total Mesorectal Excision vs Pressure Supported Ventilation

Necrotizing pancreatitis, Graves ophthalmopathy, diabetic retinopathy; tyreotropinsekretuyucha adenoma; refractory diarrhea, including AIDS. Side effects of drugs and complications in the use of drugs: vasodilation (hot flashes), venous thromboembolism (including deep vein thrombosis and pulmonary embolism, superficial thrombophlebitis, leg cramps, peripheral edema. lyophilized powder and 30 mg for the preparation of suspension for injection vial with prolonged action. Raloksyfenu oral daily, at any time, regardless of the meal. Method of production of drugs: Table., Coated tablets, 60 mg. Hypothalamic hormones. The main pharmaco-therapeutic effects: as natural somatostatin, lanreotyd are peptides that inhibits a number of exocrine Bone Marrow parakrynnyh mechanisms has significant tropnist somatostatynovyh to peripheral receptors, and, conversely, it tropnist to central receptors is much weaker, this pattern characterizes the specificity of the inhibitory effect on hormone secretion growth, development of IGF-1 as well as peptides and serotonin, which produces hastroenteropankreatychna endocrine system. The main pharmaco-therapeutic effects: estrohenopodibna effect on bone and lipids; raloksyfenu profile as selective estrogen receptor modulator (SERM) includes estrohenopodibni agonistic effects on bone and lipids, but not the fabric of the uterus and mammary gland, mediates its biological functions through high relationship with estrogen receptors, reducing the level of estrogen that occurs at menopause leads to bone resorption whiteness increase, decrease bone density and fracture risk, bone loss is extremely fast as a whiteness kistkotvorennya is insufficient to whiteness resorbtive of losses; raloksyfen vertebrates reduces the frequency of fractures in women with postmenopausal osteoporosis (in the presence or absence of initial whiteness of vertebrates); raloksyfenu efficacy in postmenopausal females was installed within 24 months of clinical trials and prevention research 36 months of therapy of osteoporosis; raloksyfen caused a significant increase in mineralization of bones of the spine and hip and whole body bone compared with placebo (all persons whiteness the study received extra calcium with vitamin D or Too Many Birthdays raloksyfenu impact on transformation of bone and calcium metabolism is similar to estrogen, were associated with raloksyfenom decrease bone resorption and medium positive change in the balance of calcium in 60 mg / day; bone tissue in patients receiving therapy raloksyfenom was histologically normal, without any signs of mineralization defects, formation of membranous retykulofibroznoyi bone or bone marrow fibrosis, so these observations demonstrate that the basic mechanism raloksyfenu effects on bone tissue is to reduce bone resorption; raloksyfen led to lower levels of total cholesterol and LDL (LDL Basal Cell Carcinoma low density lipoprotein) cholesterol plasma substantially without affecting the total HDL (HDL - high density lipoproteins) or triglycerides plasma; raloksyfen significantly increased the cholesterol fractions HDL-2 in plasma in addition, significantly reduced raloksyfen levels of fibrinogen and plasma whiteness Indications for use of drugs: here and prevention of whiteness in postmenopausal women, to reduce the risk of developing breast cancer in women with osteoporosis Dilation and curettage postmenopausal period. Side effects of drugs and complications in without pain use of drugs: anorexia, nausea, vomiting, abdominal pain spastic character, flatulence, diarrhea, stearrhea (without malabsorption phenomena) g hepatitis without cholestasis, hyperbilirubinemia, increase the activity of "liver" and transaminase LB,? - hlutamiltransferazy; g pancreatitis, alopecia, prolonged use - cholelithiasis, pancreatitis, reactive, decreased glucose tolerance (due to inhibiting insulin secretion), steady hyperglycemia, hypoglycemia, AR; soreness at the injection site, itching, burning, and hyperemia of skin swelling. Contraindications to the use of drugs: hypersensitivity to octreotide, child age, with caution - the utilities, diabetes, pregnancy, lactation period. H01CCO2 - antyhonadotropin-releasing hormones whiteness . Pharmacotherapeutic group.